join us
CN
Home page
About Us
Profile
Affiliates/Subsidiaries
Development History
Quality Management
Contact Us
Legal Statement
Adverse Reaction Report
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
News & Trends
Public information
News & Trends
28
2024-11
Salubris’innovative drugs Xinliting and FoLitan ® have been included in China's national reimbursement drug list
27
2024-08
Salubris obtaining the exclusive right of base editing drug YOLT-101
05
2024-08
The innovative anti-tumor drug JK06 was approved for overseas clinical trial
01
2024-08
Enarodustat’s new indication approved for clinical trial
31
2024-07
SAL0120 tablets for treatment of chronic kidney disease(CKD) approved for clinical trial
05
2024-07
Innovative type 2 diabetes drug Fultagliptin benzoate tablet (Xinliting) obtained marketing authorization
目前在第
1
页,
共有
10
页,
共有
58
条记录
第一页
上一页
1
2
3
4
5
下一页
最后一页
跳转到
页